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A mutant of mouse prion protein (PrPC) carrying a deletion of residues 114–121 (PrPΔ114–121) has previously been described to lack
convertibility into the scrapie-associated isoform of PrP (PrPSc) and to exhibit a dominant-negative effect on the conversion of wild-type PrPC into
PrPSc in living cells. Here we report the characterization of recombinantly expressed PrPΔ114–121 by Fourier-transformation infrared
spectroscopy (FTIR) and circular dichroism (CD) spectroscopy. The analysis of spectra revealed an increased antiparallel β-sheet content in the
deletion mutant compared to wild-type PrPC. This additional short β-sheet stabilized the fold of the mutant protein by ΔΔG0′=3.4±0.3 kJ mol−1
as shown by chemical unfolding experiments using guanidine hydrochloride. Secondary structure predictions suggest that the additional β-sheet in
PrPΔ114–121 is close to the antiparallel β-sheet in PrPC. The high-affinity Cu2+-binding site outside the octarepeats, which is located close to the
deletion and involves His110 as a ligand, was not affected, as detected by electron paramagnetic resonance (EPR) spectroscopy, suggesting that
Cu2+ binding does not contribute to the protection of PrPΔ114–121 from conversion into PrPSc. We propose that the deletion of residues 114–121
stabilizes the mutant protein. This stabilization most likely does not obstruct the interaction of PrPΔ114–121 with PrPSc but represents an energy
barrier that blocks the conversion of PrPΔ114–121 into PrPSc.
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Prions are the causative agents of transmissible spongiform
encephalopathies [1]. These fatal neurodegenerative diseases
include BSE in cattle, scrapie in sheep, and Creutzfeldt–Jakob
disease (CJD) in humans, and can be of infectious or genetic
etiology or arise spontaneously. They are characterized by the
conversion of the cellular prion protein (PrPC) into a disease-
associated isoform (PrPSc), which shows an increased β-sheet
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doi:10.1016/j.bbamcr.2007.11.007and a tendency to aggregate. It is assumed that the conversion of
PrPC to PrPSc entails the formation of a PrPC–PrPSc hetero-
dimer [2], in which PrPSc catalyzes the conversion of PrPC into
PrPSc. Although PrPSc accumulation is a hallmark of prion
diseases, it is probably not the neurotoxic molecule per se [3],
since PrPSc proved non-toxic to neurons that are lacking PrPC
expression [4,5].
PrPC, whose expression is essential for the susceptibility to
prion infection [6], is mainly expressed in neurons and is a
highly conserved cell surface protein, attached to the outer
leaflet of the cell membrane via a C-terminal glycosyl-
phosphatidylinositol (GPI) anchor. Its physiological function
remains to be elucidated, but its ability to selectively bind Cu2+
has been documented in numerous studies [7,8]. Cu2+ binding is
mediated by the N-terminal octarepeats (amino acid sequence
PHGGGWGQ) and a region close to the transmembrane (TM1)
domain involving His110 (mouse numbering) [9] (Fig. 1). In
Fig. 1. Location of deletion mutation in PrP. (A) Schematic representation of PrPC domain structure. The TM1 domain is shown in blue, deletion of aa 114–121 in
cyan; location of α-helices are indicated in red and location of β-sheets in yellow. (B) Model of PrPC using the same color code as in panel A. The N-terminal domain
of PrPC (aa 23–126), which has not been characterized structurally, is shown as an extended loop structure; the location of the octarepeats within this region is shown in
dark grey; α-helices are shown in red and β-sheets in yellow.
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PrPC, transmembrane topologies of PrPC have been described
[10,11]. These transmembrane forms are inserted into the lipid
bilayer of the endoplasmic reticulum via the TM1 domain of
PrPC, a hydrophobic stretch between residues 111 and 134,
encompassing the highly conserved hydrophobic core
AGAAAAGA (amino acids 112–119).
The first link between the TM1 domain and prion disease
became apparent by the fact that a peptide encompassing amino
acids 106–126 (human numbering) induces neurotoxic effects
in cultured primary brain cells [12–15].
Subsequently, it was shown that PrP mutants lacking the
TM1 domain or part of it are not converted into PrPSc [16].
Specifically, murine PrP mutants with deletions of residues
114–121 [17] or 112–119 [18] are not converted into PrPSc.
Moreover, the deletion of 114–121 (henceforth termed
PrPΔ114–121) led to a reduction in the level of PrPSc derived
from endogenous PrPC-wt in scrapie-infected Neuro2a cells,
i.e. the deletion mutant had a dominant-negative effect on PrPSc
accumulation [17].
Recently, we investigated in a collaborative study the effect
of PrPΔ114–121 in transgenic mice with respect to the
physiological function of PrPC [19]. We could show that the
PrPΔ114–121 mutant was not intrinsically toxic in the presence
or absence of PrPC. Co-expression of PrPΔ114–121 with other
deletion mutants showed that it alleviates the pathogenic effect
of the PrPΔ32–134 mutant, which is characterized by a
spontaneous, non-infectious neurodegenerative syndrome dis-
tinct from prion disease. By contrast, PrPΔ114–121, enhanced
the pathogenic effect of the PrPΔ94–134 deletion mutant. In
another study published simultaneously the effect of PrPΔ105–
125 in transgenic mice was investigated [20]. Both studies
concluded that PrPC acts neuroprotective via constitutive
activation of a putative PrP receptor. Conversion of PrPC into
PrPSc might disrupt the interaction between PrPC and the PrP
receptor, although the detailed molecular mechanism is still
unclear. Likewise, the mechanism underlying the inconvert-
ibility of PrPΔ114–121 into PrPSc has not been resolved so far.A key to fully understand the function of the TM1 domain in
PrP is the combination of data from different methodological
approaches such as transgenic mice, cell biological model
systems and biochemical structural studies. In this study we
investigated the structural consequences of deleting residues
114–121 in murine PrPC.
2. Materials and methods
2.1. Plasmid construction
For recombinant protein expression, the cDNA of murine PrP coding for
amino acids 23–230 was cloned into the E. coli expression vector pRSET A
(Invitrogen) yielding pRSET A::PrP-wt. The expression vector for PrPΔ114–
121, pRSET A::PrPΔ114–121, was constructed by subcloning the fragment of
PrPΔ114–121 obtained by digesting pUC19::PrPΔ114–121 [17] with Eco81I
and Eco91I (MBI-Fermentas) into pRSETA::PrP-wt. The correct insertion was
checked by DNA sequencing.
2.2. Recombinant protein expression and purification
PrP-wt and PrPΔ114–121 were expressed in E. coli BL21(DE3) as hexa-
histidine (His6)-tagged fusion proteins and purified to homogeneity as published
previously [21]. Briefly, inclusion bodies of the recombinant protein were
denatured and subjected to affinity chromatography on nickel-NTA agarose. The
protein was refolded and oxidized while immobilized on the column, followed
by elution with buffer containing imidazole. The His6-tag was then removed by
thrombin cleavage. After ion-exchange chromatography, the protein was
dialyzed against water and lyophilized. Purity was checked by SDS-PAGE.
2.3. Analytical methods
Protein concentrations of PrP-wt and PrPΔ114–121 were determined from
the absorbance at 278 nm with the specific extinction coefficient
ɛ278 nm=63.130 M
−1 cm−1 calculated from the amino acid sequence (www.
expasy.org/tools/protparam.html). The presence of the disulfide bond was
checked using disodium 2-nitro-5-sulfonatosulfanyl-benzoate [22].
2.4. CD spectroscopy
Circular dichroism (CD) spectra were recorded at 298 K with a spectro-
polarimeter J-715 (Jasco) at protein concentrations of 20 to 75 μM in 0.10 cm
and 0.01 cm quartz cells. The lyophilized protein was dissolved in 20 mM NEM
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averaged and corrected for the buffer spectrum. The secondary structure content
of PrP-wt and PrPΔ114–121 was calculated by a least-square fit according to
Chang et al. [23] implemented into the interface Dicroprot [24], which uses a
base set of four CD spectra typical for each type of secondary structure.
Furthermore the secondary structure content was assessed with the programs
SELCON [25], CONTINLL [26] and CDSSTR [27] using a base set of 43 CD
spectra of proteins with known structure. The latter 3 programs are implemented
in the interface CDPro [28].
The stability of the protein against denaturation was assessed using
guanidine hydrochloride (GdnHCl) by adding aliquots of a 7 M GdnHCl
stock solution (pH 6.0) to PrP-wt or PrPΔ114–121 (concentration: 15 μM, in
20 mM MES in D2O, pD 6.0) and measuring the ellipticity at 222 nm. The
values were recorded ten times and averaged. Assuming a two-state folding
mechanism, the difference in free energy (ΔG) between folded and unfolded
state is calculated according to Pace:
DG ¼ RT ln Fd= 1 Fdð Þ½ 
where R is the gas constant, T the absolute temperature and Fd the fraction of
unfolded protein [29]. The data from the denaturation experiments were
analyzed by a nonlinear least-square fit using the program Origin version 7.0
(Origin Lab).
2.5. FTIR spectroscopy
All measurements were performed in D2O, which does not adsorb in the
region of the amide I transitions of the peptide backbone. Lyophilized PrP was
dissolved in D2O. The pD was adjusted to 7.2 by addition of concentrated
DCl or NaOH. The samples were equilibrated overnight at room temperature
in order to achieve complete proton–deuterium exchange of the backbone
amides. The protein concentration was 150 μM throughout. Spectra were
recorded at 293 K on a Bruker Tensor 27 FTIR spectrometer accumulating
128 scans at a resolution of 2 cm−1; spectra of D2O were recorded under the
same conditions and subtracted from the sample spectra. The position of
individual IR transitions in the amide I′ region between 1700 and 1600 cm−1
was resolved by second order derivative spectra. For protein secondary
structure analysis the spectra were fitted with a set of 8 Lorentzian line shaped
transitions.
2.6. EPR spectroscopy
Spectra were recorded on a Bruker Elexsys 500 instrument, with the
following settings: microwave frequency 9.34 GHz (X-band), microwave power
0.2–4 mW, modulation frequency 100 kHz, modulation amplitude 1 mT,
temperature 22 K; 10 spectra between 240 and 380 mT were averaged for each
sample.Fig. 2. Analysis of murine PrP-wt and PrPΔ114–121 by FTIR spectroscopy. (A) Com
I′ region is deconvoluted into 8 Lorentzian line shaped IR transitions (broken lines). In
the experimental spectra (solid lines). (C) Overlay of FTIR spectra of PrP-wt and PrP
spectrum of PrPΔ114–121. The difference spectrum (PrP-wt minus PrPΔ114–121)The protein was 20 μM in 25 mM NEM buffer+20% (v/v) glycerol in D2O,
pD 7.0. Copper(II) was added as CuSO4. Only 0.9 equivalents of Cu
2+ were
added in order to selectively probe the Cu2+-binding site close the TM1 region of
PrP. The concentration of CuSO4 stock solutions was determined by flame
atomic absorption spectrometry (SpectrAA-110, Varian Inc.). The EPR samples
(250 μl, 4-mm standard quartz tube) were frozen in an iso-pentane bath cooled
with liquid nitrogen to 173 K and stored in liquid nitrogen prior to the
measurement.
3. Results
3.1. Protein expression and purification
In order to characterize the consequences of deleting aa 114–
121 for the structure of murine PrP, we expressed PrP-wt and
PrPΔ114–121 in E. coli as recombinant proteins and purified
them to homogeneity. The applied method for protein
purification and refolding was shown to yield highly structu-
rally homogenous protein preparations [21,30,31]. Both, PrP-wt
and PrPΔ114–121, contained the structurally essential disulfide
bond and displayed comparable solubility.
3.2. Structural analysis of PrP-wt and PrPΔ114–121 by FTIR
and CD spectroscopy
For the structural analysis of PrP-wt and PrPΔ114–121 at
pH 7.0, we applied FTIR spectroscopy to monitor amide I′
oscillations between 1700 and 1600 cm−1. The amide I band
represents predominantly CfO and C–N vibrations of the
peptide backbone that are sensitive towards the hydrogen
bonding pattern and thereby reflect the different types of
secondary structure. In D2O the proton of the amide group is
exchanged with the deuterium ion, and consequently the
positions of the bands shift to smaller wavenumber (amide I′
band). The FTIR spectra of PrP-wt and PrPΔ114–121 had a
very similar shape (Fig. 2A, B) except for the region around
1615 cm−1 (Fig. 2C). The transition in this region is typical for
antiparallel β-sheets, and already suggested a higher content of
antiparallel β-sheets in PrPΔ114–121. For a detailed analysis of
the secondary structure content of PrP-wt and PrPΔ114–121ponent analysis of FTIR spectrum of PrP-wt and (B) of PrPΔ114–121. The amide
panels A and B the sum of the single components (lines with diamonds) overlay
Δ114–121. The solid line represents PrP-wt, the line with circles represents the
is shown as line with triangles and exhibits a minimum at 1615 cm−1.
Table 1
Component analysis of FTIR spectra of PrP-wt and PrPΔ114–121
Secondary structure Amide I′ PrP-wt PrPΔ114–121
wavenumber
(cm1)
Secondary
structure
content (%)
Secondary
structure
content (%)
Antiparallel β-sheet 1615 10.1 11.9
Parallel β-sheet 1629 15.0 16.2
β-turn 1664, 1675 17.1 18.0
random coil 1643 35.2 31.9
α-helix 1653 22.6 22.0
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transitions (Fig. 2B). Six out of 8 transitions could be assigned
to contributions of α-helix (1652 cm−1), β-sheet (1631 cm−1),
turns (∼1664 cm−1 and ∼1676 cm−1), and random coil
(1642 cm−1) (Table 1). Two bands at 1587 and 1564 cm−1 were
assigned to contributions of amino acid sidechains. Integration
of the 6 bands revealed for both proteins a content of 22% α-
helix, 25–28% β-sheet, 17–18% β-turns, and 32–35% random
coil (Table 1). The analysis revealed clearly a structural
difference between PrP-wt and PrPΔ114–121. PrPΔ114–121
displayed a higher content of antiparallel as well as parallel β-
sheets and β-turns and correspondingly a lower random content
than PrP-wt.
In order to estimate the consequences of deleting residues
114–121 might have for the structure of PrP, we performed
secondary structure predictions for the PrP peptides aa 100–150
and the corresponding deletion mutant by nnPredict [32]. The
prediction for the wt peptide is in reasonable agreement with the
structure of mouse PrP 121–231 as determined by NMR [33].
The first β-sheet encompassing residues 128–131 is predicted
by nnPredict and there is some propensity (Fig. 3) for an α-helix
at the position of helix 1 (residues 144–153) of mouse PrP [33].
Furthermore, a long hydrophobic helix (108–119) is predicted
in the TM1 region (residues 111–134). This helix is present in
PrP when it is inserted in the membrane, whereas PrP in solution
does not show any secondary structure of this region at pH 4.5Fig. 3. Secondary structure prediction for PrPC-wt and PrPΔ114–121 residues 100–
PrPΔ114–121 are shown. Underneath, the secondary structure predictions by nnPred
(α-helix). At the bottom is shown the secondary structure of mouse PrPC as determi
predicted β-sheet 1 (128–131) as well as partially helix I of PrP. Furthermore the helix
membrane protein (Hegde et al. [10]) underlining the correct prediction by nnPredict. A
a short β-sheet.or pH 7.0 [34,35]. The prediction for the corresponding peptide
(PrP 100–150, Δ114–121) suggests that the deletion eliminates
the possibility of α-helix formation, but instead supports the
formation of another short β-sheet at residues 108–110. This
short β-sheet could align antiparallel to the existing β-sheets
and give rise to the observed signal in FTIR.
In order to substantiate the changes in secondary structure
observed by FTIR spectroscopy, we recorded CD spectra of
PrP-wt and PrPΔ114–121 for secondary structure analysis (Fig.
4). CD spectra were recorded between 180 and 260 nm, which
is a prerequisite for reliable estimates of the secondary structure
content. Overlay of the CD spectra of PrP-wt and PrPΔ114–121
revealed that the latter exhibited more intense bands around
190 nm and 208 nm, but not at 222 nm (Fig. 4A). The constant
intensity of the CD bands at 222 nm, where only α-helices
contribute significantly, suggests that the content of α-helix did
not change. The bands at 208 and 190 nm, on the other hand,
contain spectral contributions from β-sheets, β-turns and
random coil [27]. The calculated difference spectrum of
PrPΔ114–121 minus PrP-wt resembles closely the spectrum
of β-sheet structures computed from CD spectra of 15 different
proteins [23] underlining that an additional β-sheet has formed
(Fig. 4B). For a quantification of the secondary structure in PrP-
wt and PrPΔ114–121, the spectra were analyzed according to
Chang et al. [23] and with the programs SELCON [25],
CONTINLL [26] and CDSSTR [27]. The analysis revealed
again a higher β-sheet content in PrPΔ114–121, thus
corroborating the results form FTIR spectroscopy. The results
from FTIR and CD analysis are compared in Table 2.
Overall, the estimates of the secondary structure content by
both spectroscopic techniques, FTIR and CD, are in good
agreement. Noteworthy, both methods reveal that the deletion
of residues 114–121 in PrP lead to an increase of 2–3% in β-
sheet content, and a concomitant 1–3% decrease in random
coil, whereas the α-helix content stays constant. The data
demonstrate that a part of the unstructured N-terminal domain
of PrP-wt has converted into β-sheet in PrPΔ114–121. The
2–3% higher content of β-sheet of secondary structure
elements corresponds to four additional residues forming150. The sequences of mouse PrP 100–150 and the corresponding sequence of
ict [32] for both sequences is shown as shaded arrows (β-sheet) and red cylinders
ned by NMR (Riek et al.[33]). The figure illustrates that nnPredict successfully
predicted for residues 108–119 does actually form when PrPC occurs as integral
ccording to nnPredict the deletion of residues 114–121 induces the formation of
Fig. 4. (A) CD spectra of murine PrP-wt and PrPΔ114–121. The spectrum of PrP-wt is shown as a solid line (-) and the spectrum of PrPΔ114–121 as line with spheres
(-●-). (B) CD difference spectrum of PrPΔ114–121 minus PrP-wt is shown as solid line (-) in comparison with the CD spectrum of a β-sheet structure computed from
CD spectra of 15 different proteins (-▴-). The computed spectrum was adapted from Chang et al. [23] and divided by 10 to overlay with the difference spectrum.
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for an excess of ∼2 hydrogen bonds in PrPΔ114–
121compared to PrP-wt, which should stabilize protein. In
order to test if PrPΔ114–121 possesses higher conformational
stability than PrP-wt, we performed chemical denaturation
experiments.
3.3. Analysis of protein stability by chemical denaturation
PrP-wt and PrPΔ114–121 were unfolded by increasing
concentrations of the denaturing agent GdnHCl, and the
ellipticity at 222 nm was recorded. The unfolding/folding of
the C-terminal structured domain of PrP is fully reversible under
these conditions [36]. The denaturation curves for both proteins
are shown in Fig. 5. Analysis of the data by a least-square fit
[29] yielded the difference in free energy ΔG0 between folded
and unfolded state. For PrP-wt a ΔG0 of 21.4±0.3 kJ mol−1
was determined. A significantly higher stability with ΔG0
equaling to 24.8±0.4 kJ mol−1 was found for PrPΔ114–121.
The ΔΔG0 of 3.4±0.3 kJ mol−1 would account for 1–2
additional hydrogen bonds in PrPΔ114–121. Thus, the deletion
of the amino acids 114–121 in PrP results in a stabilization of
the overall protein structure.
3.4. EPR spectroscopic analysis of copper(II) binding to PrP-wt
and PrP ΔTM
The deleted residues 114–121 in PrP are located very closely
to a Cu2+ binding site that is remote from the octarepeatTable 2
Secondary structure content of PrP-wt and PrPΔ114–121
PrP Wt
Method FTIR CD
CONTINLL SELCON CDSSTR C
α-helix (%) 22.6 20.0 19.2 18.6 2
β-sheet (%) 25.1 24.9 26.5 25.6 2
β-turn (%) 17.1 21.7 22.0 22.4 2
Random coil (%) 35.2 33.4 33.4 33.3 3
Comparison of CD and FTIR data.structure [9,37]. This site coordinates Cu2+ through the
imidazole nitrogen of His111 (His110 in mouse PrP) and
most likely through backbone nitrogen or one methionine
sulphur [38–40]. In competition experiments it was shown that
peptides encompassing the TM1 domain (aa 91–115) bind Cu2+
with higher affinity than the octarepeats (aa 58–91) [9]. Cu2+
binding to this site induces β-sheet formation [9] and
conversion of PrPC into a protease-resistant species [41]. The
peptide PrP 106–126 which harbors this Cu2+-binding site, is
cytotoxic [14,42,43] to PrPC-expressing cells, and this sequence
is essential for the conversion of PrPC into PrPSc [44].
Interestingly, Cu2+ binding to this peptide promotes aggregation
and the formation of fibrils [45].
We examined the effects of deleting residues 114–121 on the
binding of Cu2+ to PrPC by EPR spectroscopy. Only 0.9
equivalents of Cu2+ per PrP-wt or PrPΔ114–121 were added.
As this site displays higher affinity to Cu2+ than do the
octarepeats, the added Cu2+ binds predominantly there [9].
EPR spectra of Cu2+-bound PrP-wt and Cu2+-bound
PrPΔ114–121 were typical of type II Cu in a square planar
geometry [46]. Both Cu–protein complexes exhibited the same
g and A parameters, g║=2.26, A║=17 mT and in the g
⊥ region a
crossover at g=2.06. There were some differences in the g⊥
region (Fig. 6A, B) which indicate the presence of a small
amount of a radical in the PrP-wt sample. The EPR parameters
g║ and A║ are sensitive to the geometry and nature of the bound
ligands. Comparison of the parameters obtained here with those
from several model compounds suggests that Cu2+ is
coordinated by a set of N/O ligands [46]. The g⊥ region wasΔ114–121
FTIR CD
hang CONTINLL SELCON CDSSTR Change
0.4 22.0 20.1 19.1 18.6 20.7
1.6 28.1 26.2 28.4 26.9 24.1
2.7 18.0 21.1 21.1 22.6 20.7
5.6 31.9 32.6 30.9 32.6 34.5
Fig. 5. Stability of murine PrP-wt and PrPΔ114–121 assessed by chemical denaturation with GdnHCl. Denaturation curves of PrP-wt (A) and PrPΔ114–121 (B) are
shown.
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to resolve for additional splittings from coordinated nitrogens
(I=1 for 14N). At least seven equidistant lines could be resolvedFig. 6. Cu2+ binding to PrP-wt and PrPΔ114–121 monitored by EPR
spectroscopy. Protein 20 µM in 25 mM NEM buffer+20% (v/v) glycerol in
D2O, pD 7.0. Instrument settings: microwave frequency, 9.342 GHz; microwave
power, 2 mW; modulation amplitude, 1 mT, temperature, 22 K. (A) Upper black
trace, PrP-wt; red trace, PrPΔ114–121. (B) g⊥ region of Cu2+-PrP-wt and Cu2+-
PrPΔ114–121. The lower traces represent the first derivative of the recorded
spectra to document the presence of additional splittings due to nitrogen
couplings.(splitting≈1.4 mT; Fig. 6B) which were attributed to nitrogen
superhyperfine coupling of 3–4 nitrogen atoms bound to Cu2+.
This is in agreement with a recent study on Cu2+-binding to the
PrP 90–126 peptide [47] and further supported by a EXAFS
study which suggests that Cu2+ is coordinated by one S and
three N atoms to the PrP 106–114 peptide [39,40]. In summary,
the Cu2+ binding to the PrP protein was marginally affected, if
at all, by the deletion of residues 114–121.
4. Discussion
In this study, we investigated the influence of the deleting
residues 114–121 of mouse PrP on protein structure, stability
and Cu2+ binding properties. Previous work in scrapie-infected
cell cultures had shown that this deletion mutant is resistant to
conversion into PrPSc [17]. FTIR spectroscopic analysis in this
study revealed a higher content of β-sheet structure in the
mutant protein. The CD spectra obtained in the present study are
very similar to those of mouse PrP 23–231 or human PrP 23–
231 in previous studies [21,34] and the CD intensity at 222 nm
of −8.000 to −9.000 deg dmol−1 cm2 demonstrate a content of
20–22% α-helix in PrP-wt (23–231). Thus, the proteins
prepared in the different studies have the same secondary
structure content. By contrast, the secondary structure content
of mouse PrP as derived from the NMR structure of mouse PrP
121–231 [33] and assuming that the N-terminal region 23–121
is not folded yields about 27.7% α-helical content. Clearly, the
secondary structure content calculated by CD and FTIR
spectroscopy deviates from the structure determined by NMR
spectroscopy. The difference is more pronounced comparing the
β-sheet content of PrPC calculated by CD and FTIR spectro-
scopy with the structural data. Again, assuming that the N-
terminal part of PrP-wt (23–121) contains no β-sheet, one
calculates the β-sheet content from the NMR structural data to
2%, whereas the CD and FTIR spectroscopic data strongly
support a β-sheet content of 25–28%. The content of β-turns in
the structures of mouse PrPC 23–231 was judged from the
structural information on mouse PrPC 121–231 and from the
structural data of three octarepeats (human PrP 61–84)
determined by NMR [48] using the program STRIDE [49].
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121 adopt a random coil conformation one calculates the β-turn
content to 22%. This value is in fair agreement with the values
obtained from FTIR and CD spectroscopy (17–21%, Table 2).
The largest uncertainty in the calculation of the secondary
structure content arises from the lack of structural data for the
N-terminal region. Two NMR studies have shown that this
region does not adopt a complete random coil conformation.
Especially the octarepeat regions form β-turns [48], and further
regions in the N-terminus encompassing at least 10 more
residues exist in mixed populations of random coil and a
structured state [50]. However, the apparent deviation in
secondary structure content determined by NMR and calculated
from CD and FTIR spectra is most likely due to incorrect
assignments of β-turn and β-sheet transition bands in FTIR as
well as in CD spectroscopy. We performed our fits and
assignments of FTIR bands in agreement with recent FTIR
studies on PrP [51–53] or general studies on protein secondary
structure analysis [54]. However, there is also a detailed
spectroscopic study on β-turns, where the authors assign a band
around 1640 cm−1 of the amide I region (i.e. ∼1635 cm−1 in
D2O) to β-turn instead to β-sheets [55]. The situation is similar
in CD spectroscopy. A study showed that the β-turns type I and
type II contribute differently to the CD spectrum and can largely
overlay the bands of β-sheet structures [56]. Therefore the
quantification of all secondary structure components by FTIR
and CD spectroscopy remains difficult. Nevertheless, the
comparison of the spectra of PrPC-wt and PrPΔ114–121 yields
valuable information on structural changes in the deletion
mutant. We identified an increase of a band centered at
1615 cm−1 in the amide I′ region of PrPΔ114–121 (Fig. 3). The
assignment of this band to antiparallel β-sheets is well
established and is evidence for an additional short β-sheet in
PrPΔ114–121. In general, antiparallel β-sheets are more
reliably estimated from FTIR spectra than from CD spectra
[54]. The analysis of the CD spectra of PrP-wt and PrPΔ114–
121 (Fig. 4B) supports this observation (Table 2). The formation
of a short β-sheet encompassing residues 110–112 in
PrPΔ114–121 is also suggested by nnPredict (Fig. 3). It is in
proximity to β-sheet 1 and might arrange antiparallel to this
structure, thus stabilizing this region as confirmed by unfolding
experiments using chemical denaturation (Fig. 5). The folding
energy of PrP-wt 23–231 of −21.4±0.3 kJ mol−1 was very
similar to the value determined by Hornemann and Glockshuber
[36] for PrP 121–231 with ΔG0 =−21.8±1.4 kJ mol−1 at pH
7.0 in 20 mM sodium phosphate buffer, suggesting that the N-
terminal region does not significantly contribute to the overall
stability of the protein. The increased stability of PrPΔ114–121
with a folding energy of −24.8±0.4 kJ mol−1 accounts for
approximately 1 or 2 additional hydrogen bonds, as expected by
the formation of a short strand of antiparallel β-sheet.
The small changes in the overall structure of PrPΔ114–121
compared to PrP-wt argue for an at least partial preservation of
PrP's physiological function. This is supported by our recent
observation that expression of PrPΔ114–121 in mice on a
Prp−/− background, which did not cause any pathogenic effect
by itself, diminished the pathogenic effect of the deletionmutant PrPΔ32–134 in transgenic mice [19] although the
rescue effect was weaker than that of PrP-wt [57,58]. In stark
contrast, co-expression of PrPΔ114–121 aggravated the
pathogenic effect of another deletion mutant, PrPΔ94–134
(termed PrPΔCD), that is rescued by PrP-wt [19], which is clear
evidence for a fundamental difference between PrPΔ114–121
and PrP-wt at the functional level. Interestingly, our recent
topology studies revealed that deletion of residues 114–121
leads to the complete loss of the transmembrane topology and of
α-cleavage of PrPC [59].
The structural changes in PrPΔ114–121 discovered in the
present work point to two possible mechanisms of how the
deletion of residues 114–121 might abolish the conversion into
PrPSc. The first possibility is that the region around the deletion
is required for transient destabilization followed by structural
conversion of PrPC into PrPSc as indicated by several studies
[17,18,44,60]. The minimal infectious unit is represented by
PrPSc that is based on the conversion of “PrPC106”, represent-
ing a molecule with deletion of both, residues 23–88 and 141–
176, yet comprising the region 90–121 [16]. It was shown that
the region around residues 109–120 undergoes a major
conformational change in PrPSc, since antibodies directed
against this region recognize PrPC but not PrPSc [61]. Therefore
some structural change in the TM1 region seems to be required
for the transition of PrPC into PrPSc. Our results suggest that in
PrPΔ114–121 this region is stabilized by an additional β-sheet,
which might represent an additional energetic barrier blocking
the pathway of PrPC to PrPSc conversion. Although a study by
Liemann and Glockshuber [62] has shown that destabilization
of PrPC is not a general mechanism underlying the formation of
PrPSc, the reverse conclusion that stabilization of PrPC blocks
conversion to PrPSc still can hold true. Indeed a study by
Baskakov et al. [63] strongly supports this hypothesis.
Baskakov et al. demonstrated that there is an energetic barrier
between the α-helical state and the energetically favored β-
sheet rich state. The α-helical PrPC is kinetically trapped in a
local minimum separated by a large energetic barrier from the
β-sheet rich state, which is most likely similar to PrPSc. Thus,
the increase of the energetic barrier by a stabilization of
PrPΔ114–121 forms a deeper trap for the α-helical PrPC and
blocks conversion into PrPSc.
The second possibility of how the conversion of PrPΔ114–
121 into PrPSc might be blocked is the loss of the binding site
between PrPC and PrPSc. Association between PrPC and PrPSc
is required for the conversion of PrPC and PrPSc accumulation.
Norstrom and Mastrianni [18] presented evidence that the
palindromic sequence AGAAAAGA (residues 112–119) is
necessary for the binding of PrPC to PrPSc. One cannot exclude
that the binding occurs also via neighboring residues close to
the palindromic sequence. We observed that the deletion of
residues 114–121 led to the formation of a short β-sheet most
likely close to this site. Deletion of residues 112–119 may well
result in a similar structural change. Such a conformational
change might cover the recognition site between PrPC and PrPSc
and therefore block the conversion of PrPΔ114–121 into PrPSc.
However, the second possibility describing the loss of the
binding site in PrPΔ114–121 cannot explain the observed
1083B. Thaa et al. / Biochimica et Biophysica Acta 1783 (2008) 1076–1084phenotype of a dominant-negative effect on prion propagation
[17]. The first model presented above including an additional
β-sheet that energetically blocks the conversion of PrPΔ114–
121 into PrPSc can indeed provide an explanation for the
observed dominant-negative effect. The overall similar struc-
ture between PrPΔ114–121 and PrPC-wt still enables the
binding of the mutant to PrPSc. The deletion, however, renders
the molecule inert with respect to the conversion process. This
will break the chain of PrPSc accumulation and should
ultimately prevent disease progression. Future prion inocula-
tion studies of the transgenic mice carrying the PrPΔ114–121
gene [19] will be instrumental to verify in vivo the model
proposed here.
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